Mixed cryoglobulinemia (MC) is an autoimmune/B-cell lymphoproliferative disorder associated with Hepatitis C Virus (HCV) infection, manifesting as a systemic vasculitis. In the last decade, antiviral treatment (AT) with pegylated interferon (Peg-IFN) plus ribavirin (RBV) was considered the first therapeutic option for HCV-MC. In MC patients ineligible or not responsive to antivirals, the anti-CD20 monoclonal antibody rituximab (RTX) is effective. A combined AT plus RTX was also suggested. Since the introduction of direct acting antivirals (DAAs), few data were published about MC and no data about a combined schedule. Here, we report a complete remission of MC after a sustained virological response following a combined RTX/Peg-IFN+RBV+DAA (boceprevir) treatment and review the literature about the combined RTX/AT.

Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy / Urraro, Teresa; Gragnani, Laura; Piluso, Alessia; Fabbrizzi, Alessio; Monti, Monica; Fognani, Elisa; Boldrini, Barbara; Ranieri, Jessica; Zignego, Anna Linda. - In: CASE REPORTS IN IMMUNOLOGY. - ISSN 2090-6609. - STAMPA. - 2015:(2015), pp. 1-5. [10.1155/2015/816424]

Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy

URRARO, TERESA;GRAGNANI, LAURA;PILUSO, ALESSIA;FABBRIZZI, ALESSIO;MONTI, MONICA;FOGNANI, ELISA;BOLDRINI, BARBARA;RANIERI, JESSICA;ZIGNEGO, ANNA LINDA
2015

Abstract

Mixed cryoglobulinemia (MC) is an autoimmune/B-cell lymphoproliferative disorder associated with Hepatitis C Virus (HCV) infection, manifesting as a systemic vasculitis. In the last decade, antiviral treatment (AT) with pegylated interferon (Peg-IFN) plus ribavirin (RBV) was considered the first therapeutic option for HCV-MC. In MC patients ineligible or not responsive to antivirals, the anti-CD20 monoclonal antibody rituximab (RTX) is effective. A combined AT plus RTX was also suggested. Since the introduction of direct acting antivirals (DAAs), few data were published about MC and no data about a combined schedule. Here, we report a complete remission of MC after a sustained virological response following a combined RTX/Peg-IFN+RBV+DAA (boceprevir) treatment and review the literature about the combined RTX/AT.
2015
2015
1
5
Goal 3: Good health and well-being for people
Urraro, Teresa; Gragnani, Laura; Piluso, Alessia; Fabbrizzi, Alessio; Monti, Monica; Fognani, Elisa; Boldrini, Barbara; Ranieri, Jessica; Zignego, Anna Linda
File in questo prodotto:
File Dimensione Formato  
CRII2015-816424.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 549.38 kB
Formato Adobe PDF
549.38 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1084584
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 27
social impact